Selected Grants
A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease
Clinical TrialPrincipal Investigator · Awarded by Novo Nordisk, Inc. · 2025 - 2027Achieving Understanding of the Natural history of sickle cell Trait (AUNT)
ResearchCollaborating Investigator · Awarded by National Alliance for Sickle Cell Centers · 2024 - 2026A Phase 3 Study of Eltrombopag vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2019 - 2026Hematology & Transfusion Medicine (T32)
Inst. Training Prgm or CMEPreceptor · Awarded by National Heart, Lung, and Blood Institute · 1975 - 2026PROTOCOL AG348-C-008 Pyruvate Kinase Deficiency Global Longitudinal Registry
Clinical TrialPrincipal Investigator · Awarded by Agios Pharmaceuticals, Inc. · 2018 - 2026AG348-C-023
Clinical TrialPrincipal Investigator · Awarded by Agios Pharmaceuticals, Inc. · 2022 - 2026Education and Mentoring to Bring Access to Comprehensive Care (EMBRACE) Network
Public ServiceHematologist · Awarded by University of Alabama at Birmingham · 2017 - 2025Environmental Modifiers of Severity in Children with Sickle Cell Anemia (EMS-SCA)
ResearchCo Investigator · Awarded by ASH Registry Inc d/b/a ASH Research Collaborative · 2024 - 2025A Phase 2, Multicenter, Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab, with or without Hydroxyurea/Hydroxycarbamide, in Sequential, Descending Age Groups of Pediatric Sickle Cell Disease Patients with Vaso-Occl
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2018 - 2025A phase II, open-label, non-controlled, intrapatient dose escalation study to characterize the pharmacokinetics after oral administration of eltrombopag in pediatric patients with refractory, relapsed or treatment naiive severe aplastic anemia or rec
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2017 - 2024North Carolina Sickle Cell Data Collection
Public ServiceCo Investigator · Awarded by NC Department of Health and Human Services · 2024 - 2024AG348-C-011 extension study of adult subjects with Pyruvate Kinase Deficiency
Clinical TrialPrincipal Investigator · Awarded by Agios Pharmaceuticals, Inc. · 2019 - 2024A Phase 3b, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an Open-label Extension Phase to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects with Immun
Clinical TrialPrincipal Investigator · Awarded by DOVA Pharmaceuticals · 2021 - 2024NCDHHS Sickle Cell Data Collection Program in North Carolina Year 3
Public ServiceCo Investigator · Awarded by NC Department of Health and Human Services · 2022 - 2023ITP-APPS (Immune ThrombocytoPenia Association of Platelet Parameters Study)
ResearchPrincipal Investigator · Awarded by Boston Children's Hospital · 2019 - 2023Real-World Treatment Patterns and Outcomes in Patients with Hemophagocytic Lymphohistiocytosis (HLH) and other Clinical Conditions Treated with Emapalumab across Treatment Centers in the US (REAL-HLH Study)
ResearchPrincipal Investigator · Awarded by SOBI · 2021 - 2023Phase III study of AG-348 in not regulary transfused adult subjects with Pyruvate kinase deficiency
Clinical TrialPrincipal Investigator · Awarded by Agios Pharmaceuticals, Inc. · 2018 - 2023Study on caplacizumab-treated pediatric patients
ResearchPrincipal Investigator · Awarded by Sanofi US · 2022 - 2023Sickle Cell Data Collection Program in North Carolina
Public ServiceCo Investigator · Awarded by NC Department of Health and Human Services · 2021 - 2022FACTOR Conference Travel Award
ConferencePrincipal Investigator · Awarded by MIB Agents Inc. · 2022 - 2022AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY OF RIVIPANSEL (GMI-1070) IN THE TREATMENT OF ONE OR MORE VASOOCCLUSIVE CRISES IN HOSPITALIZED SUBJECTS WITH SICKLE CELL DISEASE
Clinical TrialCo Investigator · Awarded by Pfizer, Inc. · 2016 - 2021CSA - Pfizer 212511 B5201002 Phase 3 Randomized Multicenter Trial
Clinical TrialCo-Principal Investigator · Awarded by Pfizer, Inc. · 2015 - 2021Pediatric Hydroxyurea Phase III Clinical Trial (Baby Hug): Follow-Up Observational Study II
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2017 - 2018ICON 1
ResearchPrincipal Investigator · Awarded by Boston Children's Hospital · 2013 - 2017PKD Natural Study
ResearchPrincipal Investigator · Awarded by Boston Children's Hospital · 2014 - 2017TCD With Transfusions Changing to Hydroxyurea (TWITCH) Closeout
ResearchPrincipal Investigator · Awarded by Cincinnati Children's Hospital Medical Center · 2014 - 2015External Relationships
- Sobi Pharmaceuticals
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.